Brain metastases of non-small cell lung cancer: prognostic factors and management

##plugins.themes.academic_pro.article.sidebar##

Published Sep 4, 2018
Download
pdf
Vol. 96 No. 3 (2018): Issue Mar 2018

##plugins.themes.academic_pro.article.main##

Saoussen Bacha
Hela Cherif
Della Rabaa
Sonia Habibech
Sana Cheikhrouhou
Hager Racil
Naouel Chaouch
Mohamed Lamine Megdiche
Abdellatif Chabbou

Abstract

Background: The prognosis of patients with non-small cell lung cancer (NSCLC) with brain metastasis (BM) is dark. The aim of our study was to analyze the prognostic factors after the onset of BM and to evaluate the current management of BM.
Methods: We conducted a retrospective study that included 100 patients diagnosed with primary NSCLC with BM. Survival was analysed using Kaplan Meier curve.Univariate survival analysis was performed to assess the prognostic value of sex, age, gender, performance status, histologic type, tumor size, BM features and treatment modality of primary lung tumor and BM.
Results:The median age was 57 years; 94% of the patients were male. Most patients (85%) had a PS of (0-1). BM were unique in 54% of cases, symptomatic in 40% of cases and synchronous in 72% of cases. Chemotherapy was administered to 78% of patients; pulmonary tumor surgery was performed in 5% of patients. BM surgery and panencephalic irradiation were performed in 13% and 86% of patients, respectively. The median overall survival after NSCLC diagnosis was 13.33 months. The median overall survival after BM was 10.6 months. The Control of the primary tumor was the only factor associated with better overall survival (64.95 months Vs 10.6 months (p=0.02)).
Conclusion: Pulmonary tumor control with complete surgical excision is predictive of better overall survival in patients with NSCLC and BM.

Keywords:

Broncho pulmonary tumor, brain metastasis, prognosis, management, survival

##plugins.themes.academic_pro.article.details##

References

  1. Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J Neuro Oncol 2005;75(1):5-14.
  2. Fabi A, Felici A, Metro G, Mirri A, Bria E, Telera S, et al. Brain Metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center. J ExpClin Cancer Res 2011;30:10.
  3. Nussbaum ES, Djalilian HR, Cho KH, Hall WA. Brain metastases: Histology, multiplicity, surgery, and survival. Cancer 1996;78:1781-8.
  4. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J RadiatOncolBiol Phys 1999;43(4):795-803.
  5. Lorenzoni J, Devriendt D, Massager N, David P, Ruiz S, Vanderlineden B, et al. Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J RadiatOncolBiol Phys 2004;60(1):218-24.
  6. Rades D, Dunst J, Schild SE. A new scoring system to predicting the survival of patients treated with whole-brain radiotherapy for brain metastases. StrahlentherOnkol 2008;184:251-5.
  7. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other index for patients with brain metastases: an analysis of 1960 patients in the RTOG database. Int J RadiatOncolBiolPhys2008;70(2):510-4.
  8. Weltman E, Salvajoli JV, Brandt RA, De Morais Hanriot R, Priscco FE, Cruz JC, et al. Radiosurgery for brain metastases: a score index for predicting prognosis. Int J RadiatOncolBiol Phys 2000;46(5):1155-61.
  9. Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosedbrain metastases: a multi-institutional analysis of 4259 patients. Int J RadiatOncolBiol Phys 2010;77(3):655-61.
  10. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis specific tool to estimate survival for patients with brain metastases. J ClinOncol 2012;30(4):419-25.
  11. Golden DW, Lamborn KR, Dermott MW, Kunwar S, Wara WM, Nakamura JL, et al.Prognostic factors and grading systems for overall survival in patients treated with radiosurgery for brain metastases: variation by primary site. J Neurosurg2008;77-86.
  12. Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J ClinOncol2005;23(25):6207-19.
  13. Ampil F, Calditto G, Milligan S, Mills G, Nanda A. The elderly with synchronous non-small cell lung cancer and solitary brain metastasis: does palliative thoracic Radiotherapy have a useful role? Lung Cancer 2007;57(1):60-5.
  14. Chaubet HM, Besse B. Métastases cérébrales des cancers bronchiques non à petites cellules : traitement systémique. Bull Cancer 2013;100(1):95-8.
  15. Quan AL, Videtic GM, Suh JH. Brain metastases in small cell lung cancer. Oncology 2004;18(8):961-72.
  16. Besse B, LeMoulec S, Senellart H, Mazières J, Barlesi F, Dansin E, et al. Final overall survival results of a non-comparative phase II study of bevacizumab plus first-line chemotherapy or second-line erlotinib (E) in non-squamous NSCLC patients with asymptomatic untreated brain metastases. J ClinOncol 2013;31(1):8059.
  17. Lang EF, Slater J. Metastatic brain tumors. Results of surgical and non-surgical treatment. SurgClin North Am 1964;44:865-72.
  18. Posner JB. Neurological complications of systemic cancer. Med Clin North Am 1971;55(3):625-46.
  19. Sanchez J, Sojo Gonzalez MA, Montero MV, Perez Calvo MC, Vicente MJ, Valle MH. Non-small cell lung cancer and silent brain metastasis. Survival and prognostic factors. Lung Cancer 2009;63(1):140-5.
  20. Gong X, Zhou D, Liang S, Zhou C. Analyses of prognostic factors in cases of non-small cell lung cancer with multiple brain metastases. Oncol Targets Ther2016;9:977-83.
  21. Ali A, Goffin MD, Arnold A, Ellis PM. Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. CurrOncol2013;20(4):300-6.
  22. Antoni D, Clavier JB, Truntzer P, Pop M, Shumacher C, Lefebre F, et al. Facteurs pronostiques de prise en charge thérapeutique des métastases cérébrales : analyse rétrospective de 777 cas. Cancer Radiother2013;17:337-48.
  23. Agboola O, Benoit B, Da Silva V, Lesiuk H, Gonsalves C. Prognostic factors derived from recursive partition analysis (RPA) of radiation therapy oncology group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases. Int J Radiation Oncology Biol Phys 1998;42(1):155-9.
  24. Kaul D, Angelidis A, Budach V, Ghadjar P, Kufeld M, Badakhshi H. Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer. RadiatOncol 2015;10:244.
  25. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Summary Report on the Graded Prognostic Assessment : An accurate and facile Diagnosis-specific tool to estimate survival for patients with brain metastases; J ClinOncol 2012;30(4):419-25.
  26. Fujita A, Fukuoka S, Takabatake H, Tagaki S, Sekine K. Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer. Oncology 2000;59(4):291-5.
  27. Kaba SE, Kyritsis AP, Hess K, Yung WK, Mercier R, Dakhil S, et al. Chemotherapy for the treatment of recurrent metastatic brain tumors. J ClinOncol 1997;15(3):1063-70.
  28. Chao ST, Barnett GH, Liu SW, Reuther AM, Toms SA, Vogelbaum MA, et al. Five-year survivors of brain metastases: a single institution report of 32 patients. Int J RadiatOncolBiol Phys 2006;66(3):801-9.
  29. Hall WA, Djalilian HR, Nussbaum ES, Cho KH. Long-term survival with metastatic cancer to the brain. Med Oncol 2000;17(4):279-86.
  30. Niemiec M, GÅ‚ogowski M, Tycsepaniak D, Wierzchowski M, Epka LK. Characteristics of long-term survivors of brain metastases from lung cancer. Rep PractOncolRadiother2011;16(2):49-53.
  31. Kondziolka D, Martin JJ, Flickinger JC, Friedland DM, Brufsky AM, Baar J, et al. Long-term survivors after gammaknife radiosurgery for brain metastases, Cancer2005;104(12):2784-91.
  32. Penel N, Brichet A, Prevost B, Duhamel A, Assaker R, Dubois F, et al. Prognostic factors of synchronous brain metastases from lung cancer. Lung cancer 2001;33(2):143-54.
  33. Shi AA, Digumarthy SR, Temel JS, Halpern EF, Kuester LB, Aquino SL. Does initial staging or tumor histology better identify asymptomatic brain metastases in patients with non-small cell lung cancer? J ThoracOncol2006;1:205-10.
  34. Hochstenbag MM, Twijnstra A, Hofman P, Wouters EFM, Tenvelde GPM. MR-imaging of the brain of neurologic asymptomatic patients with large cell or adenocarcinoma of the lung. Does it influence prognosis and treatment? Lung Cancer 2003;42:189-93.
  35. American Society of Clinical Oncology clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J ClinOncol1997;15(8):2996-3018.
  36. Gelber RD, Larson M, Borgelt BB, Kramer S. Equivalence of radiation schedules for the palliative treatment of brain metastases in patients with favorable prognosis. Cancer 1981;48:1749-53.
  37. Mintz AH, Kestle J, Rathbone MP, Gaspar L, Hugenhozh, Fisher B, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996;78(7):1470-6.
  38. Chan RC, Steinbok P. Solitary cerebral metastasis: The effect of craniotomy on the quality and the duration of survival. Neurosurgery 1982;11(2):254-7.
  39. Collaud S, Stahel R, Inci I, Hillinger S, Schneiter D, Kestenholz P, et al. Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TNM stage. Lung Cancer 2012;7(3)8:234-8.
  40. Maclean J, Fersht N, Singhera M, Hillinger S, Schneiter D, Kestenholz P, et al. Multidisciplinary management for patients with oligometastases to the brain: results of a 5 year cohort study. RadiatOncol2013;8:156.
  41. Gray PJ, Mak RH, Yeap BY, Cryer SK, Sher DJ, Swanson SJ, et al. Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival. Lung Cancer 2014;85(2):239-44.
  42. Jacot W, Quantin JM, Boher JM, Andre F, Morceau L, Gainet M, et al. Brain metastases at the time of presentation of non-small cell lung cancer: a multicentric AERIO analysis of prognostic factors. B J Cancer 2000;84(7):903-9.
  43. Vogelbaum MA, Suh JH. Resectablebrainmetastases. J Clin Oncol 2006;24:1289-94.
  44. Jacot W, Quantin JM, Boher JM, Andre F, Morceau L, Gainet M, et al. Brain metastases at the time of presentation of non-small cell lung cancer: a multicentric AERIO analysis of prognostic factors. B J Cancer 2000;84(7):903-9.
  45. Kelly K, Bunn PA. It is time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? Lung Cancer 1998;20:85-91.
  46. Kim SY, Kim JS, Park HS, Cho MJ, Kim JO, Kim JV, et al. Screening of brain metastasis with limited magnetic resonance imaging (MRI): clinical implications of using limited brain MRI during initial staging for non-small cell lung cancer patients. J Korean Med Sci2005;20:121-6.
  47. Vogelbaum MA, Suh JH. Resectablebrainmetastases. J Clin Oncol 2006;24:1289-94.
  48. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastasis to the brain N Eng J Med. 1990;322:494-500.
  49. Vecht CJ, Haaxma-Reiche H, Noorrdjik, Padberg GW, Voolmen JH, Hoekstra FH, et al. Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgery? Ann Neurol1993;33(6):583-90.
  50. Taillibert S, Le Rhun É. Épidémiologie des lésions métastatiques cérébrales. Cancer Radiother 2015;19:3-9.
  51. Tendulkar RD, Liu SW, Barnett GH, Vogelbaum MA, Tom SA, Jin T, et al. RPA classification has prognostic significance for surgically resected single brain metastasis. Int J RadiatOncolBiol Phys 2006;66(3):810-7.
  52. Noordijk EM, Vecht CJ, Haaxma-Reiche H, Padberg GW, Voormolen JH, Hoekstra FH, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J RadiatOncolBiol Phys 1994;29(4):711-7.
  53. Vogelbaum MA, Suh JH. Resectable brain metastases. J ClinOncol 2006;24(8):1289-94.
  54. Khuntia D, Brown P, Li J, Mehta MP. Whole-brain radiotherapy in the management of brain metastasis. J ClinOncol2006;24:1295-304.
  55. Kurup P, Reddy S, Hendrickson FR. Results of re-irradiation for cerebral metastases. Cancer 1980;46:2587-9.
  56. Wong WW, Schild SE, Sawyer TE, Shaw EG. Analysis of outcome in patients reirradiated for brain metastases. Int J RadiatOncolBiol Phys 1996;34:585-90.
  57. Loeffler JS, Kooy HM, Wen PY, Fine HA, Cheng CW, Mannarino EG, et al. The treatment of recurrent brain metastases with stereotactic radiosurgery. J ClinOncol 1990;8(4):576-82.
  58. Arbit E, Wronski M, Burt M, Galicich JH. The treatment of patients with recurrent brain metastases. A retrospective analysis of 109 patients with non-small cell lung cancer. Cancer 1995;76:765-73.
  59. Hazuka MB, Burleson WD, Stroud DN, Leonard CE, Lillehei KO, Kinzie JJ. Multiple brain metastases are associated with poor survival in patients treated with surgery and radiotherapy. J ClinOncol 1993;11:369-73.
  60. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin RJ, Cryscio RJ, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998;280(17):1485-9.